Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab

Colocci, Natalia; Weller, Edie; Hochster, H. S.; Gascoyne, R.; Kumm, B.; Ryan, Timothy; Habermann, Thomas M.; Frankel, S. R.; Horning, S. J.

doi:10.1200/jco.2005.23.16_suppl.6526

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several phase III trials of patients treated with CVP with or without a subsequent maintenance treatment with rituximab [7], with CVP with or without rituximab [8], and with ibritumomab (a radiolabeled murine anti-CD20 monoclonal antibody) [9], the FLIPI discriminated patients with significantly different progression-free survivals. Thus, initial progression-free survival has been tested as a surrogate for overall survival.…”

Section: Follicular Lymphoma International Prognostic Indexmentioning

confidence: 99%

Follicular lymphoma international prognostic index

Solal‐Céligny

2006

Curr. Treat. Options in Oncol.

317

375

View full text Add to dashboard Cite

Section: Follicular Lymphoma International Prognostic Indexmentioning

confidence: 99%

Follicular lymphoma international prognostic index

Solal‐Céligny

2006

Curr. Treat. Options in Oncol.

317

375

View full text Add to dashboard Cite

“…The FLIPI is discriminant for initial progressionfree survival in all trials of patients initially treated with R-CVP [7], CVP followed by R [8], R-CHOP [9]. The median PFS is significantly different between each FLIPI subgroup.…”

mentioning

confidence: 96%

What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma?

Solal‐Céligny

2007

Leukemia & Lymphoma

View full text Add to dashboard Cite

Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission

Brown

Feng

Gribben

et al. 2007

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The role of autologous stem cell transplantation (ASCT) in the treatment of follicular lymphoma is still being defined in the era of antibody therapy. Here we report the long-term 12-year clinical outcomes of patients treated with autologous bone marrow transplantation (ABMT) for follicular non-Hodgkin's lymphoma (NHL) in first remission. Between 1988 and 1993, advanced-stage follicular NHL patients in need of initial therapy were enrolled in 2 consecutive prospective treatment trials of either standard-dose CHOP induction (83 patients) or high-dose CHOP plus granulocyte-colony stimulating factor (G-CSF) (20 patients). Patients who achieved an adequate remission with induction therapy underwent conditioning with cyclophosphamide and total body irradiation (TBI) followed by ABMT in first remission using bone marrow (BM) purged in vitro with anti-B cell monoclonal antibodies and rabbit complement (96 patients). At 12-year follow-up, 61% of the patients are alive and 43% remain in continuing complete remission. The only predictors of decreased progression-free survival proved to be histologic BM involvement at time of harvest (hazard ratio [HR] 2.27, 95% confidence interval [CI] 1.3-3.9, P<.004) and PCR detectable disease in the BM product after purging (HR 4.18, 95% CI 1.99-8.8, P=.0002). No significant predictors of overall survival were identified. These results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged survival with ABMT in first remission.

show abstract

Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab

Cited by 4 publications

References 0 publications

Follicular lymphoma international prognostic index

Follicular lymphoma international prognostic index

What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma?

Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission

Contact Info

Product

Resources

About